Alzheimer’s Treatment Market Size and Share Analysis Report: Forecast Trends and Outlook (2026-2035)

Alzheimer’s Treatment Market Overview

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting over 6.9 million Americans aged 65 and older, with global cases around 44 million.  The treatment market is anticipated to grow at a CAGR of 7.20% during the forecast period of 2026-2035. It leads to memory loss, cognitive decline, and behavioural changes, causing significant mortality and economic burden, costs in the U.S. reached USD 360 billion in 2024. Current treatments focus on symptom relief using cholinesterase inhibitors and memantine, while research continues on disease-modifying therapies targeting amyloid plaques and tau proteins to slow progression.

Alzheimer’s Treatment Market Growth Drivers

New Approvals Driving Alzheimer’s Treatment Market Expansion Worldwide

For instance, increasing demand for early-intervention therapies and rising investment in neurodegenerative drug R&D are fuelling market growth. For instance, in May  2025, Eisai and Biogen announced that the U.S. FDA accepted a Supplemental Biologics License Application (sBLA) for Leqembi as a maintenance treatment for early Alzheimer’s. The application seeks to enable less frequent dosing after initial therapy. This development could significantly improve patient compliance and accessibility, boosting long-term market adoption of disease-modifying Alzheimer’s treatments.

Surge in Government Approvals to Boost Alzheimer’s Treatment Market Demand

The rising prevalence of early-stage Alzheimer’s and the push for region-specific drug approvals are key market drivers. For instance, in May  2025, Australia approved donanemab (marketed as Kisunla), an anti-amyloid drug for early Alzheimer’s, following its U.S. success. The approval supports expanding access to cutting-edge treatments across new geographies. This move is poised to strengthen market value in the Asia-Pacific region, encouraging faster adoption and increased regional regulatory momentum in Alzheimer’s care.

Alzheimer’s Treatment Market Trends

Alzheimer’s Treatment Market Segmentation

Alzheimer’s Treatment Market Share

Cholinesterase Inhibitors to Lead the Segmentation by Drug Class

Cholinesterase inhibitors are set to lead the market due to their proven efficacy in managing mild to moderate symptoms. Drugs like donepezil, rivastigmine, and galantamine help enhance neurotransmitter activity, improving memory and cognitive function. Their widespread prescription, long-established clinical use, and minimal safety concerns contribute to continued demand. As the aging population grows, these therapies will remain essential, supported by ongoing clinical enhancements and rising public and professional awareness about early-stage Alzheimer’s management.

Hospital Pharmacy Dominating the Segment by Distribution Channel

Hospital pharmacies are expected to lead the market by end user due to their role in initiating treatment following formal diagnosis. Complex Alzheimer’s medications often require physician supervision, which hospital settings efficiently provide. Hospitals also serve as primary sites for clinical trials and new therapy rollouts. With the growing number of specialized neurology departments and inpatient care units for cognitive disorders, hospital pharmacies will remain central to drug dispensing, driving sustained market development.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Alzheimer’s Treatment Market Analysis by Region

The United States has the largest Alzheimer’s treatment market. Several factors drive this, such as, an aging population, early diagnosis rates, significant healthcare spending, and rapid adoption of new drugs. Medicare covers many treatments, and recent FDA approvals (like Leqembi and donanemab) have stirred both interest and debate. The market is competitive, with major pharmaceutical companies investing heavily in R&D. Public pressure and advocacy groups keep Alzheimer’s high on the policy agenda. In the United Kingdom, the NHS plays a central role in market dynamics. Access to newer treatments is slower due to NICE cost-effectiveness evaluations. The focus is on early intervention and non-drug therapies, though biologics are gaining attention. Government funding for dementia research has increased, but uptake of novel drugs remains cautious.

Leading Players in the Alzheimer’s Treatment Market

Other key players in the market include Baxter International Inc., Abbvie, Inc., Eisai Co. Ltd., Merz Pharma, AstraZeneca, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., ONO Pharmaceutical Industries Ltd., VTV Therapeutics, and Biogen.

Key Questions Answered in the Alzheimer’s Treatment Market

• What was the Alzheimer’s treatment market value in 2025?
• What is the Alzheimer’s treatment market forecast outlook for 2026-2035?
• What are the major factors aiding the Alzheimer’s treatment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Alzheimer’s treatment market trends?
• Which drug class will lead the market segment?  
• Which end user will lead the market segment?
• Who are the key players involved in the Alzheimer’s treatment market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?